


Senescence in normal and cancer cells

Jesús Gil

Introduction to senescence and the molecular mechanisms controlling it.



Senescence is an irreversible growth arrest




Leonard Hayflick



Primary cell



Senescent cell



Senescence comes in different flavours: Oncogene-Induced Senescence


Cell, Vol. 88, 593-602, March 7, 1997, Copyright ©1997 by Cell Press

Oncogenic *ras* Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16^{INK4a}




Manuel Serrano


Senescence is a potent tumor suppressor mechanism




Senescence and its physiological relevance



“HAYFLICK” factors limit cell proliferation




How do cells count their divisions?



James Watson

3' _____ dsDNA
_____ 3' (chromosome)

Telomere shortening ↓ DNA copy




telomeres

telomeres



“End replication problem”

Telomerase and senescence




How do cells count their divisions?


The *INK4b-ARF-INK4a* locus



Transcriptional control of the *INK4a/ARF* locus




ARF activates p53




Copyright © 2006 Nature Publishing Group
Nature Reviews | Molecular Cell Biology



Regulation of cell cycle by p16^{INK4a}



How do cells count their divisions?




Telomere uncapping activates the DNA damage pathway




Activation of p53 during senescence





DNA damage as a common mediator of senescence signaling



A model for oncogene action in senescence




Hayflick factors



Relevance of senescence for cancer and aging

Telomerase and aging




premature aging syndromes

- Ataxia telangiectasia (ATM)
- Werner syndrome (WRN)
- Bloom syndrome (BLM)
- Dyskeratosis congenica (DKC1, Terc)
- Aplastic anemia (Terc, Tert)
- Fanconi anemia (Fanc genes)
- Nijmegen breakage syndrome (Nbs)


Telomerase limits life

Ink4a/Arf expression is a biomarker of aging

Janakiraman Krishnamurthy,¹ Chad Torrice,¹ Matthew R. Ramsey,¹ Grigoriy I. Kovalev,²
Khalid Al-Regaiey,² Lishan Su,² and Norman E. Sharpless³




Increase in replicative senescence during aging




The relation between stem cells, senescence and aging

- Bmi1 KO mice have defects in stem cell self-renewal, partially due to deregulated *Ink4a/Arf*.




The main tumor suppressor pathways are involved in senescence




senescence = tumor suppression ?

Telomerase and cancer




senescence = tumor suppression ?


oncogene activation



Myc



apoptosis



RasV12




senescence



Tumor suppressor mechanisms

In vivo?

“c- Myc activation in vivo induces apoptosis”




“And apoptosis is a tumor suppressor mechanism”

c-MycER^{TAM} x BclXL-KO = ↑↑↑ tumors




Stella Pelengaris and Gerard Evan [Cell](#) 2002

Oncogene-induced senescence is a barrier for cancer progression




Nature (2005). 436



Nat Med. (2005) 11


<i>Lesion</i>	<i>Study</i>
Human melanocytic nevi	Michaloglou et al., 2005; Gray-Schopfer et al., 2006
Murine lung adenomas	Collado et al., 2005; Dankort et al., 2007
Human dermal neurofibromas	Courtis-Cox et al., 2006
Human and murine prostate PIN lesions	Chen et al., 2005
Murine pancreatic intraductal neoplasias	Collado et al., 2005
Murine papillomas	Collado et al., 2005
Murine lymphomas	Braig. et al., 2005
Early murine melanomas	Ha et al., 2007

Mouse models show a role for p53 in aging




What we do in our lab?

Senescence can be exploited to identify novel cancer genes in vitro




***Unveiling novel regulators of senescence
using genetic screenings***


Genetic screens for lifespan extension




Genetic screens for bypass of replicative senescence



• NKI pRETROSUPER library



shRNAs identified so far



p53

Rb


ARK5 (EMBO J, 2009 in press)

TOP1 (Cancer Res., 2009)

PLA2 (EMBO Rep, 2009)




CXCR2 (Cell, 2008)

CXCR2 signaling




Senescence ?

CXCR2 depletion impairs the activation of the DNA damage response



Coordinated upregulation of CXCR2 and its ligands in senescence


CXCR2 ligands





Antibody arrays


CXCR2

Oncogene-induced senescence




Replicative senescence





Upregulation of CXCR2 in senescent premalignant lesions


DMBA/TPA: skin papillomas




- Premalignant lesions
- 100 % Activating H-Ras mutations

Collado *et al.* Nature (2005)


Cxcr2



Cxcr2 ligands





Prostate intraepithelial neoplasia (PIN)



- Premalignant lesions
- Precursor of prostate cancer (Pca)

Chen *et al.* Nature (2005)

CXCR2



Maria Guijarro (Eva Hernando's lab.)

In which other context is senescence relevant?

Induced pluripotent stem cells: the Yamanaka factors

Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

Kazutoshi Takahashi¹ and Shinya Yamanaka^{1,2,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

*Contact: yamanaka@frontier.kyoto-u.ac.jp

DOI 10.1016/j.cell.2006.07.024

Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors

Kazutoshi Takahashi,¹ Koji Tanabe,¹ Mari Ohnuki,¹ Megumi Narita,^{1,2} Tomoko Ichisaka,^{1,2} Kiichiro Tomoda,³ and Shinya Yamanaka^{1,2,3,4,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan


²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

³Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA


⁴Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8507, Japan

*Correspondence: yamanaka@frontier.kyoto-u.ac.jp

DOI 10.1016/j.cell.2007.11.019




Reprogramming: complex, slow, inefficient and dangerous




- **Complex** involves several steps, including chromatin modifications and global expression patterns alterations
- **Inefficient** and **slow**, has to overcome several barriers
- The mechanisms behind the switch to pluripotency/self-renewal remain mostly unknown


Expression of reprogramming factors induces senescence







Reprogramming factors cause growth arrest




Induction of effectors of senescence



Chromatin remodeling of the *Ink4a/Arf* locus during reprogramming




Activation of the p53/p21 pathways at multiple points during RIS




Pluripotency-related miRNAS inhibit senescence


Low expression of pluripotency-related miRNAs in cells suffering RIS




Partial bypass of senescence by forced expression of miR-302




Regulation of p21 by miR-302



Parallels between oncogene and reprogramming-induced senescence




Senescence disabled






Inhibition of senescence increases reprogramming efficiency

Knocking down senescence effectors with shRNA




Increase in reprogramming efficiency




Improving reprogramming from the technical point of view

'Standard' Reprogramming




Low efficiency

Inhibition of DNA methylation




Increased proportion of Fully vs. Partial reprogrammed iPS

Inhibition of senescence



Increased numbers of both Fully and Partial reprogrammed iPS

Senescence and its physiological relevance





<http://cellpro.csc.mrc.ac.uk>



Juan Carlos Acosta

Ana Banito

Ana O’Loghlen

Nikolay Popov

Selina Raguz


Nadine Martin

Marta Barradas

Rita Franca

Sadaf Khan

We are funded by:



Collaborators

David Bernard CNRS, Lille

Gordon Peters lab (Emma Anderton) LRI London

Martin Walsh lab (SiDe Li) Mount Sinai, NY

Eva Hernando/J. Melamed NYU

Fabrizio d’Adda di Fagagna (M Fumagalli) IFOM, Milan

Mariano Barbacid/Carmen Guerra CNIO, Madrid